Concepts (166)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug Overdose | 10 | 2025 | 126 | 3.640 |
Why?
|
| Analgesics, Opioid | 8 | 2025 | 487 | 2.390 |
Why?
|
| Opioid-Related Disorders | 7 | 2025 | 457 | 1.740 |
Why?
|
| Narcotic Antagonists | 6 | 2025 | 121 | 1.630 |
Why?
|
| Naloxone | 7 | 2025 | 57 | 1.540 |
Why?
|
| Cannabinoids | 3 | 2024 | 38 | 1.300 |
Why?
|
| Fentanyl | 2 | 2017 | 72 | 1.070 |
Why?
|
| Emergency Service, Hospital | 5 | 2021 | 1022 | 1.030 |
Why?
|
| Substance Abuse Detection | 3 | 2024 | 44 | 0.940 |
Why?
|
| Benzodiazepines | 1 | 2024 | 94 | 0.880 |
Why?
|
| Accidental Falls | 1 | 2024 | 124 | 0.840 |
Why?
|
| Ethanol | 2 | 2024 | 306 | 0.820 |
Why?
|
| Buprenorphine | 2 | 2023 | 182 | 0.800 |
Why?
|
| Drug Contamination | 2 | 2017 | 15 | 0.710 |
Why?
|
| Drug Users | 1 | 2021 | 28 | 0.700 |
Why?
|
| Salvia | 2 | 2012 | 3 | 0.690 |
Why?
|
| Mitragyna | 4 | 2016 | 5 | 0.670 |
Why?
|
| RNA, Viral | 1 | 2021 | 259 | 0.670 |
Why?
|
| Naltrexone | 1 | 2019 | 77 | 0.590 |
Why?
|
| Antidotes | 3 | 2016 | 20 | 0.590 |
Why?
|
| Chromatography, Liquid | 2 | 2017 | 127 | 0.590 |
Why?
|
| Heroin Dependence | 1 | 2017 | 22 | 0.570 |
Why?
|
| Heroin | 1 | 2017 | 12 | 0.560 |
Why?
|
| Saliva | 1 | 2017 | 100 | 0.550 |
Why?
|
| Poisoning | 2 | 2015 | 31 | 0.540 |
Why?
|
| Chronic Pain | 1 | 2019 | 136 | 0.540 |
Why?
|
| Phenytoin | 1 | 2016 | 18 | 0.520 |
Why?
|
| Drug Hypersensitivity Syndrome | 1 | 2016 | 5 | 0.520 |
Why?
|
| Mass Spectrometry | 1 | 2017 | 296 | 0.510 |
Why?
|
| Exanthema | 1 | 2016 | 26 | 0.510 |
Why?
|
| Anticonvulsants | 1 | 2016 | 88 | 0.500 |
Why?
|
| Epilepsy | 1 | 2016 | 105 | 0.480 |
Why?
|
| Self Report | 1 | 2017 | 359 | 0.470 |
Why?
|
| Psychotropic Drugs | 2 | 2012 | 81 | 0.440 |
Why?
|
| Sodium Acetate | 1 | 2013 | 2 | 0.430 |
Why?
|
| Energy Drinks | 1 | 2012 | 4 | 0.390 |
Why?
|
| Cyclohexylamines | 1 | 2012 | 5 | 0.390 |
Why?
|
| Cyclohexanones | 1 | 2012 | 5 | 0.390 |
Why?
|
| Humans | 26 | 2025 | 59454 | 0.390 |
Why?
|
| Alkaloids | 1 | 2012 | 11 | 0.390 |
Why?
|
| Piperazines | 1 | 2012 | 74 | 0.370 |
Why?
|
| Caffeine | 2 | 2023 | 47 | 0.300 |
Why?
|
| Young Adult | 6 | 2023 | 4274 | 0.300 |
Why?
|
| Rubiaceae | 1 | 2008 | 3 | 0.300 |
Why?
|
| Receptors, Opioid | 1 | 2008 | 14 | 0.290 |
Why?
|
| Plant Preparations | 1 | 2008 | 15 | 0.290 |
Why?
|
| Wireless Technology | 2 | 2020 | 18 | 0.290 |
Why?
|
| Male | 13 | 2024 | 27784 | 0.280 |
Why?
|
| Harm Reduction | 2 | 2025 | 29 | 0.270 |
Why?
|
| Emergency Medical Services | 2 | 2025 | 256 | 0.270 |
Why?
|
| Toxicology | 3 | 2016 | 33 | 0.270 |
Why?
|
| Drug Substitution | 2 | 2016 | 40 | 0.240 |
Why?
|
| Adolescent | 7 | 2021 | 5851 | 0.230 |
Why?
|
| Trauma Centers | 1 | 2024 | 114 | 0.210 |
Why?
|
| Buprenorphine, Naloxone Drug Combination | 1 | 2023 | 25 | 0.210 |
Why?
|
| Secologanin Tryptamine Alkaloids | 2 | 2016 | 2 | 0.210 |
Why?
|
| Adult | 9 | 2023 | 15697 | 0.210 |
Why?
|
| Community Health Services | 1 | 2023 | 120 | 0.190 |
Why?
|
| Wounds and Injuries | 1 | 2024 | 229 | 0.190 |
Why?
|
| Renal Dialysis | 1 | 2023 | 189 | 0.190 |
Why?
|
| Post-Concussion Syndrome | 1 | 2021 | 5 | 0.190 |
Why?
|
| Alprazolam | 1 | 2021 | 4 | 0.190 |
Why?
|
| Brain Concussion | 1 | 2021 | 31 | 0.180 |
Why?
|
| Benzamides | 1 | 2021 | 63 | 0.180 |
Why?
|
| Massachusetts | 3 | 2025 | 2022 | 0.180 |
Why?
|
| Prevalence | 1 | 2024 | 1255 | 0.170 |
Why?
|
| Geographic Information Systems | 1 | 2020 | 20 | 0.170 |
Why?
|
| United States | 2 | 2024 | 7432 | 0.170 |
Why?
|
| Female | 7 | 2024 | 30766 | 0.160 |
Why?
|
| Methadone | 1 | 2019 | 127 | 0.150 |
Why?
|
| Urinalysis | 1 | 2017 | 30 | 0.140 |
Why?
|
| Pilot Projects | 1 | 2021 | 916 | 0.140 |
Why?
|
| Copper Sulfate | 1 | 2017 | 3 | 0.140 |
Why?
|
| Chelation Therapy | 1 | 2017 | 4 | 0.140 |
Why?
|
| Stomach Diseases | 1 | 2017 | 10 | 0.140 |
Why?
|
| Phytotherapy | 2 | 2008 | 52 | 0.140 |
Why?
|
| Accidents | 1 | 2017 | 14 | 0.140 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 1028 | 0.140 |
Why?
|
| Gastric Mucosa | 1 | 2017 | 51 | 0.140 |
Why?
|
| Coloring Agents | 1 | 2017 | 53 | 0.140 |
Why?
|
| Opiate Substitution Treatment | 1 | 2019 | 188 | 0.140 |
Why?
|
| Gas Poisoning | 1 | 2016 | 1 | 0.130 |
Why?
|
| Hydrogen Cyanide | 1 | 2016 | 1 | 0.130 |
Why?
|
| Evidence-Based Emergency Medicine | 1 | 2016 | 2 | 0.130 |
Why?
|
| Smoke Inhalation Injury | 1 | 2016 | 3 | 0.130 |
Why?
|
| Narcotics | 1 | 2016 | 50 | 0.130 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 2008 | 119 | 0.130 |
Why?
|
| Pandemics | 1 | 2021 | 617 | 0.130 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 527 | 0.130 |
Why?
|
| Remission Induction | 1 | 2016 | 137 | 0.130 |
Why?
|
| Fructose | 1 | 2016 | 36 | 0.130 |
Why?
|
| Attitude to Computers | 1 | 2015 | 21 | 0.120 |
Why?
|
| Videoconferencing | 1 | 2015 | 11 | 0.120 |
Why?
|
| Remote Consultation | 1 | 2015 | 18 | 0.120 |
Why?
|
| Infusions, Intravenous | 2 | 2013 | 163 | 0.120 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2015 | 43 | 0.120 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2016 | 168 | 0.120 |
Why?
|
| Aged, 80 and over | 1 | 2024 | 5126 | 0.120 |
Why?
|
| Medical Marijuana | 1 | 2014 | 18 | 0.110 |
Why?
|
| Prospective Studies | 2 | 2020 | 3072 | 0.110 |
Why?
|
| Sodium Bicarbonate | 1 | 2013 | 11 | 0.110 |
Why?
|
| Automobile Driving | 1 | 2014 | 55 | 0.110 |
Why?
|
| Vascular Resistance | 1 | 2013 | 48 | 0.110 |
Why?
|
| Time Factors | 2 | 2021 | 3621 | 0.100 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 1560 | 0.100 |
Why?
|
| Risk Assessment | 1 | 2019 | 1926 | 0.100 |
Why?
|
| Referral and Consultation | 1 | 2015 | 406 | 0.100 |
Why?
|
| Drug Interactions | 1 | 2012 | 115 | 0.090 |
Why?
|
| Aged | 3 | 2024 | 13424 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 805 | 0.090 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 552 | 0.090 |
Why?
|
| Nervous System Diseases | 1 | 2012 | 104 | 0.090 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 2383 | 0.090 |
Why?
|
| Hydromorphone | 1 | 2008 | 5 | 0.080 |
Why?
|
| Self Medication | 1 | 2008 | 14 | 0.080 |
Why?
|
| Child | 2 | 2021 | 4201 | 0.070 |
Why?
|
| Diterpenes, Clerodane | 1 | 2008 | 1 | 0.070 |
Why?
|
| Diterpenes | 1 | 2008 | 19 | 0.070 |
Why?
|
| Chlorpheniramine | 1 | 2007 | 1 | 0.070 |
Why?
|
| Phenylpropanolamine | 1 | 2007 | 2 | 0.070 |
Why?
|
| Dextromethorphan | 1 | 2007 | 3 | 0.070 |
Why?
|
| Serotonin Syndrome | 1 | 2007 | 9 | 0.070 |
Why?
|
| Propofol | 1 | 2007 | 21 | 0.070 |
Why?
|
| Treatment Outcome | 2 | 2016 | 5287 | 0.070 |
Why?
|
| Hypnotics and Sedatives | 1 | 2007 | 62 | 0.070 |
Why?
|
| Acetaminophen | 1 | 2007 | 49 | 0.070 |
Why?
|
| Molecular Structure | 1 | 2008 | 375 | 0.070 |
Why?
|
| Risk Factors | 1 | 2016 | 4990 | 0.060 |
Why?
|
| Self Care | 1 | 2007 | 207 | 0.060 |
Why?
|
| Mental Disorders | 1 | 2012 | 720 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2012 | 789 | 0.060 |
Why?
|
| Animals | 2 | 2013 | 19667 | 0.050 |
Why?
|
| Suicide, Attempted | 1 | 2023 | 105 | 0.050 |
Why?
|
| Sampling Studies | 1 | 2021 | 66 | 0.050 |
Why?
|
| Heart | 1 | 2023 | 274 | 0.050 |
Why?
|
| Dietary Supplements | 2 | 2016 | 222 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2021 | 272 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 470 | 0.040 |
Why?
|
| Algorithms | 2 | 2016 | 979 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2017 | 117 | 0.030 |
Why?
|
| Hydroxocobalamin | 1 | 2016 | 1 | 0.030 |
Why?
|
| Decision Trees | 1 | 2016 | 51 | 0.030 |
Why?
|
| Point-of-Care Testing | 1 | 2016 | 44 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2016 | 142 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 454 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 354 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2016 | 99 | 0.030 |
Why?
|
| Plant Extracts | 1 | 2016 | 163 | 0.030 |
Why?
|
| Poison Control Centers | 1 | 2014 | 6 | 0.030 |
Why?
|
| Industry | 1 | 2014 | 59 | 0.030 |
Why?
|
| Dronabinol | 1 | 2014 | 31 | 0.030 |
Why?
|
| Equipment Design | 1 | 2015 | 330 | 0.030 |
Why?
|
| Medical Informatics | 1 | 2014 | 67 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 310 | 0.030 |
Why?
|
| Psychomotor Performance | 1 | 2014 | 133 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2015 | 526 | 0.030 |
Why?
|
| Middle Aged | 3 | 2017 | 16335 | 0.030 |
Why?
|
| Software | 1 | 2015 | 366 | 0.020 |
Why?
|
| Biomarkers | 1 | 2016 | 1306 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 725 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2015 | 748 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2007 | 147 | 0.020 |
Why?
|
| Attitude | 1 | 2007 | 97 | 0.020 |
Why?
|
| Internet | 1 | 2007 | 448 | 0.010 |
Why?
|
| Substance-Related Disorders | 1 | 2007 | 687 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2007 | 2517 | 0.010 |
Why?
|